PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
Jupiter Neurosciences signed a definitive license agreement with PharmAla Biotech to secure exclusive, perpetual U.S. rights to ALA-002, a patented MDMA formulation with FDA New Chemical Entity designation. The transaction structure includes total potential consideration of up to $100 million, consisting of a $3.3 million upfront payment split between cash and equity, plus nearly $97 million in contingent regulatory and sales-based milestones.
Key figures
- Drug Name
- ALA-002
- Deal Value Usd
- US$100 million
- Royalty rate
- 3%
- Upfront cash
- US$1,500,000
- Upfront stock
- US$1,833,333
- Upfront payment total
- US$3,333,333
- Development milestones
- US$23,333,333
- Commercialization milestones
- US$73,333,333
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.